Livzon Pharmaceutical Group has been identified as an investor by Elicio Therapeutics, which just completed a series B round that takes its total financing to $63m.

CareStack's latest round attracted Delta Dental of California and will be used to extend the dental management software provider's customer base.

Icosavax has launched out of University of Washington with $51m in series A funding to move a vaccine for respiratory syncytial virus into a phase 1b trial.

Frequency, a regenerative medicine developer based on MIT and Harvard research, priced shares at the bottom of its range to raise $84m in its IPO.

The Alexandria Real Estate Equities-backed regenerative medicine developer floated at the bottom of its range while cutting the number of shares.

The genome mapping system developer took its total funding past the $100m mark in a round led by Hitachi High-Technologies.

Samsung, OCI, Regeneron, Handok, Johnson & Johnson and existing investor Novartis all took part in the cell therapy developer's latest round.

CSU Ventures boosted its licensing income by more than two-fold and established six new spinouts during the 2018-19 academic year.

Returning investor BGI took part in a series B round for the cancer diagnostics technology developer that included fellow corporate UEC.

Returning investors Agilent Technologies and Alexandria Venture Investments chipped into a $12.2m round for the DNA synthesis technology developer.